Skip to main content

Volume 15 - Issue 1 - January 2018

January 2018 Issue 1 Volume 15

Editorial
VASCULAR DISEASE MANAGEMENT 2018;15(1):E6-E7.
John A. Phillips, MD, FSCAI, RPVI
We evaluated our 1- and 2-year patency rates as well as the clinically driven reintervention rates in our patients with diffuse de novo and instent restenotic FP atherosclerotic lesions greater than 20 cm who received the Zilver PTX DES.
Case Report
VASCULAR DISEASE MANAGEMENT 2017;15(1):E3-E5.
Arnaldo Poli, MD1; Andrea Baldo, MD2; Paola Martina, MD1; Erica Ferrara, MD1; Luigi Vittonati, MD1; Germano Di Credico, MD1 1ASST Ovest Milanese, Ospedale di Legnano, Italy, Cardiology Department; 2University of Pavia, Pavia, Italy, Cardiology Division.
Severe iliofemoral arteriopathies precludes transfemoral access in approximately one-third of patients, but subclavian access represents an alternative option for these patients.
Editor's Corner
VASCULAR DISEASE MANAGEMENT 2018;15(1):E1-E2
Craig Walker, MD
Dr. Walker comments on Poli and colleagues’ article on the implantation of the ACURATE neo transcatheter aortic valve to treat a patient with severe aortic stenosis via a subclavian artery that was surgically exposed.
ISET Spotlight
VASCULAR DISEASE MANAGEMENT 2018;15(1):E8-E10
Superficial femoral artery (SFA) is an area of intense research interest and multiple options for treatment. In this Q&A, Gary Ansel, MD, FACC, explains the takeaways from recently released data on various devices and therapies.
Back to Top